The absence of CCK2R expression in normal, healthy surrounding tissues and overexpression in the tumor environment provides favorable opportunities for high-contrast diagnostic imaging and radionuclide therapy of these tumors, making CCK2R an excellent target for the development of radiolabeled peptides for diagnosis and therapy in nuclear medicine. The gene discussed is CCKBR; the disease is neoplasm.